Key clinical point: Laparoscopic proximal gastrectomy (LPG) and laparoscopic total gastrectomy (LTG) lead to similar long-term outcomes and postoperative complications in patients with upper third clinical stage I gastric cancer.

Major finding: Patients who underwent LPG and LTG showed no significant difference in the 3-year overall survival (92.6% and 92.3%, respectively; P = .74), recurrence-free survival (both 85.3%; P = .72), early complication (eg, surgical site infection; P = .31), and late complication (eg, anastomotic stenosis; P = .31) rates.

Study details: This retrospective study propensity score-matched patients with upper third clinical stage I gastric cancer who underwent LTG (n = 28) and those who underwent LPG (n = 28).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Yamamoto M et al. Laparoscopic proximal gastrectomy with novel valvuloplastic esophagogastrostomy vs laparoscopic total gastrectomy for stage I gastric cancer: A propensity score matching analysis. J Gastrointest Surg. 2022 (Aug 29). Doi: 10.1007/s11605-022-05404-y

Key clinical point: Laparoscopic proximal gastrectomy (LPG) and laparoscopic total gastrectomy (LTG) lead to similar long-term outcomes and postoperative complications in patients with upper third clinical stage I gastric cancer.

Major finding: Patients who underwent LPG and LTG showed no significant difference in the 3-year overall survival (92.6% and 92.3%, respectively; P = .74), recurrence-free survival (both 85.3%; P = .72), early complication (eg, surgical site infection; P = .31), and late complication (eg, anastomotic stenosis; P = .31) rates.

Study details: This retrospective study propensity score-matched patients with upper third clinical stage I gastric cancer who underwent LTG (n = 28) and those who underwent LPG (n = 28).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Yamamoto M et al. Laparoscopic proximal gastrectomy with novel valvuloplastic esophagogastrostomy vs laparoscopic total gastrectomy for stage I gastric cancer: A propensity score matching analysis. J Gastrointest Surg. 2022 (Aug 29). Doi: 10.1007/s11605-022-05404-y

Key clinical point: Laparoscopic proximal gastrectomy (LPG) and laparoscopic total gastrectomy (LTG) lead to similar long-term outcomes and postoperative complications in patients with upper third clinical stage I gastric cancer.

Major finding: Patients who underwent LPG and LTG showed no significant difference in the 3-year overall survival (92.6% and 92.3%, respectively; P = .74), recurrence-free survival (both 85.3%; P = .72), early complication (eg, surgical site infection; P = .31), and late complication (eg, anastomotic stenosis; P = .31) rates.

Study details: This retrospective study propensity score-matched patients with upper third clinical stage I gastric cancer who underwent LTG (n = 28) and those who underwent LPG (n = 28).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Yamamoto M et al. Laparoscopic proximal gastrectomy with novel valvuloplastic esophagogastrostomy vs laparoscopic total gastrectomy for stage I gastric cancer: A propensity score matching analysis. J Gastrointest Surg. 2022 (Aug 29). Doi: 10.1007/s11605-022-05404-y

Key clinical point: Modern perioperative chemotherapy (PC) combined with minimally invasive surgery (MIS) improves lymph node yield and long-term survival without affecting postoperative morbidity in operable gastric cancer.

Major finding: Compared with surgery in 2005-2010, that in 2016-2021 and 2011-2015 was associated with adjusted hazard ratios (95% CI) for overall 3-year mortality of 0.37 (0.20-0.68) and 1.02 (0.63-1.66), respectively. Surgery in 2016-2021 vs 2005-2010 led to significantly increased median lymph node yield (23 vs 17; P < .001) but similar major complication rates (15.5% vs 12.3%; P = .736).

Study details: This real-world retrospective study included 181 patients with gastric or esophagogastric junction adenocarcinoma who underwent curative intent surgery in years 2005-2010 (open surgery+adjuvant therapy; n = 65), 2011-2015 (PC+MIS adopted; n = 58), and 2016-2021 (PC+MIS standard practice; n = 58).

Disclosures: This study was sponsored by the Instrumentarium Science Foundation, Helsinki, Finland, among others. The authors declared no conflicts of interest.

Source: Junttila A et al. Implementation of multimodality therapy and minimally invasive surgery: Short- and long-term outcomes of gastric cancer surgery in medium-volume center. J Gastrointest Surg. 2022 (Aug 24). Doi: 10.1007/s11605-022-05437-3

Key clinical point: Modern perioperative chemotherapy (PC) combined with minimally invasive surgery (MIS) improves lymph node yield and long-term survival without affecting postoperative morbidity in operable gastric cancer.

Major finding: Compared with surgery in 2005-2010, that in 2016-2021 and 2011-2015 was associated with adjusted hazard ratios (95% CI) for overall 3-year mortality of 0.37 (0.20-0.68) and 1.02 (0.63-1.66), respectively. Surgery in 2016-2021 vs 2005-2010 led to significantly increased median lymph node yield (23 vs 17; P < .001) but similar major complication rates (15.5% vs 12.3%; P = .736).

Study details: This real-world retrospective study included 181 patients with gastric or esophagogastric junction adenocarcinoma who underwent curative intent surgery in years 2005-2010 (open surgery+adjuvant therapy; n = 65), 2011-2015 (PC+MIS adopted; n = 58), and 2016-2021 (PC+MIS standard practice; n = 58).

Disclosures: This study was sponsored by the Instrumentarium Science Foundation, Helsinki, Finland, among others. The authors declared no conflicts of interest.

Source: Junttila A et al. Implementation of multimodality therapy and minimally invasive surgery: Short- and long-term outcomes of gastric cancer surgery in medium-volume center. J Gastrointest Surg. 2022 (Aug 24). Doi: 10.1007/s11605-022-05437-3

Key clinical point: Modern perioperative chemotherapy (PC) combined with minimally invasive surgery (MIS) improves lymph node yield and long-term survival without affecting postoperative morbidity in operable gastric cancer.

Major finding: Compared with surgery in 2005-2010, that in 2016-2021 and 2011-2015 was associated with adjusted hazard ratios (95% CI) for overall 3-year mortality of 0.37 (0.20-0.68) and 1.02 (0.63-1.66), respectively. Surgery in 2016-2021 vs 2005-2010 led to significantly increased median lymph node yield (23 vs 17; P < .001) but similar major complication rates (15.5% vs 12.3%; P = .736).

Study details: This real-world retrospective study included 181 patients with gastric or esophagogastric junction adenocarcinoma who underwent curative intent surgery in years 2005-2010 (open surgery+adjuvant therapy; n = 65), 2011-2015 (PC+MIS adopted; n = 58), and 2016-2021 (PC+MIS standard practice; n = 58).

Disclosures: This study was sponsored by the Instrumentarium Science Foundation, Helsinki, Finland, among others. The authors declared no conflicts of interest.

Source: Junttila A et al. Implementation of multimodality therapy and minimally invasive surgery: Short- and long-term outcomes of gastric cancer surgery in medium-volume center. J Gastrointest Surg. 2022 (Aug 24). Doi: 10.1007/s11605-022-05437-3

Key clinical point: Lymph node ratio (LNR) may serve as an independent prognosis predictor in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy (NACT).

Major finding: Patients with a low vs high LNR had significantly longer 3-year overall survival (OS; 81.9% vs 18.5%; P < .001) and progression-free survival (PFS; 72.6% vs 13.5%; P < .001) rates. Multivariate analysis revealed LNR to be the only independent predictive factor for both OS (adjusted hazard ratio [aHR] 6.90; P < .001) and PFS (aHR 5.58; P < .001).

Study details: This retrospective study included 148 patients with LAGC who underwent NACT and radical gastrectomy and were categorized to have a low (≤30%; n = 103) or high (>30%; n = 45) LNR.

Disclosures: This study was sponsored by the National Natural Science Foundation of China and the Natural Science Foundation of Hubei Province. The authors declared no conflicts of interest.

Source: Jiang Q et al. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy. World J Surg Oncol. 2022;20(1):261 (Aug 17). Doi: 10.1186/s12957-022-02725-9

Key clinical point: Lymph node ratio (LNR) may serve as an independent prognosis predictor in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy (NACT).

Major finding: Patients with a low vs high LNR had significantly longer 3-year overall survival (OS; 81.9% vs 18.5%; P < .001) and progression-free survival (PFS; 72.6% vs 13.5%; P < .001) rates. Multivariate analysis revealed LNR to be the only independent predictive factor for both OS (adjusted hazard ratio [aHR] 6.90; P < .001) and PFS (aHR 5.58; P < .001).

Study details: This retrospective study included 148 patients with LAGC who underwent NACT and radical gastrectomy and were categorized to have a low (≤30%; n = 103) or high (>30%; n = 45) LNR.

Disclosures: This study was sponsored by the National Natural Science Foundation of China and the Natural Science Foundation of Hubei Province. The authors declared no conflicts of interest.

Source: Jiang Q et al. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy. World J Surg Oncol. 2022;20(1):261 (Aug 17). Doi: 10.1186/s12957-022-02725-9

Key clinical point: Lymph node ratio (LNR) may serve as an independent prognosis predictor in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy (NACT).

Major finding: Patients with a low vs high LNR had significantly longer 3-year overall survival (OS; 81.9% vs 18.5%; P < .001) and progression-free survival (PFS; 72.6% vs 13.5%; P < .001) rates. Multivariate analysis revealed LNR to be the only independent predictive factor for both OS (adjusted hazard ratio [aHR] 6.90; P < .001) and PFS (aHR 5.58; P < .001).

Study details: This retrospective study included 148 patients with LAGC who underwent NACT and radical gastrectomy and were categorized to have a low (≤30%; n = 103) or high (>30%; n = 45) LNR.

Disclosures: This study was sponsored by the National Natural Science Foundation of China and the Natural Science Foundation of Hubei Province. The authors declared no conflicts of interest.

Source: Jiang Q et al. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy. World J Surg Oncol. 2022;20(1):261 (Aug 17). Doi: 10.1186/s12957-022-02725-9

Key clinical point: A reduction in the treatment cycle number of adjuvant chemotherapy with S-1 (Tegafur+ 5-chloro-2-4-dihydroxypyridine+oxonic acid) or capecitabine/oxaliplatin (CAPOX) in gastric cancer results in poorer survival outcomes.

Major finding: The 5-year overall survival rates in patients who received S-1 gradually increased from 48.4% to 55.4%, 64.1%, 71.1%, and 77.9% with an increase in cycle number from ≤5 to ≥8 cycles (P < .0001), with the same trend being observed with CAPOX (≤4 to ≥8 cycles: 43.5%, 45.3%, 47.1%, 55.3%, and 67.2%; P < .0001).

Study details: This retrospective study included 20,552 patients with gastric cancer who received 12-month S-1 (n = 13,614) or 6-month CAPOX (n = 6938) adjuvant chemotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Kim TH et al. Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: A retrospective nationwide cohort study. BMC Cancer. 2022;22(1):948 (Sep 3). Doi: 10.1186/s12885-022-10006-7

Key clinical point: A reduction in the treatment cycle number of adjuvant chemotherapy with S-1 (Tegafur+ 5-chloro-2-4-dihydroxypyridine+oxonic acid) or capecitabine/oxaliplatin (CAPOX) in gastric cancer results in poorer survival outcomes.

Major finding: The 5-year overall survival rates in patients who received S-1 gradually increased from 48.4% to 55.4%, 64.1%, 71.1%, and 77.9% with an increase in cycle number from ≤5 to ≥8 cycles (P < .0001), with the same trend being observed with CAPOX (≤4 to ≥8 cycles: 43.5%, 45.3%, 47.1%, 55.3%, and 67.2%; P < .0001).

Study details: This retrospective study included 20,552 patients with gastric cancer who received 12-month S-1 (n = 13,614) or 6-month CAPOX (n = 6938) adjuvant chemotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Kim TH et al. Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: A retrospective nationwide cohort study. BMC Cancer. 2022;22(1):948 (Sep 3). Doi: 10.1186/s12885-022-10006-7

Key clinical point: A reduction in the treatment cycle number of adjuvant chemotherapy with S-1 (Tegafur+ 5-chloro-2-4-dihydroxypyridine+oxonic acid) or capecitabine/oxaliplatin (CAPOX) in gastric cancer results in poorer survival outcomes.

Major finding: The 5-year overall survival rates in patients who received S-1 gradually increased from 48.4% to 55.4%, 64.1%, 71.1%, and 77.9% with an increase in cycle number from ≤5 to ≥8 cycles (P < .0001), with the same trend being observed with CAPOX (≤4 to ≥8 cycles: 43.5%, 45.3%, 47.1%, 55.3%, and 67.2%; P < .0001).

Study details: This retrospective study included 20,552 patients with gastric cancer who received 12-month S-1 (n = 13,614) or 6-month CAPOX (n = 6938) adjuvant chemotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Kim TH et al. Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: A retrospective nationwide cohort study. BMC Cancer. 2022;22(1):948 (Sep 3). Doi: 10.1186/s12885-022-10006-7

Key clinical point: Tumor mutational burden (TMB) status is associated with the clinical outcomes of the first-line pembrolizumab-based therapy in patients with advanced gastric cancer.

Major finding: TMB was significantly associated with the objective response rate, progression-free survival, and overall survival in the pembrolizumab monotherapy and pembrolizumab-chemotherapy treatment groups (1-sided P < .05) but not in the chemotherapy group (2-sided P > .05).

Study details: This prespecified exploratory analysis included 306 patients with advanced gastric cancer and evaluable TMB data who received pembrolizumab alone, pembrolizumab+chemotherapy, or chemotherapy alone in the phase 3 KEYNOTE-062 trial (n = 763).

Disclosures: This study was sponsored by Merck Sharp & Dohme (MSD) LLC, a subsidiary of Merck & Co., Inc., NJ Some authors reported receiving grants or personal fees from various sources, including MSD and Merck. Two authors declared being employees of MSD or Merck.

Source: Lee KW et al. Association of tumor mutational burden with efficacy of pembrolizumab±chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 2022;28(16):3489-3498 (Aug 15). Doi: 10.1158/1078-0432.CCR-22-0121

Key clinical point: Tumor mutational burden (TMB) status is associated with the clinical outcomes of the first-line pembrolizumab-based therapy in patients with advanced gastric cancer.

Major finding: TMB was significantly associated with the objective response rate, progression-free survival, and overall survival in the pembrolizumab monotherapy and pembrolizumab-chemotherapy treatment groups (1-sided P < .05) but not in the chemotherapy group (2-sided P > .05).

Study details: This prespecified exploratory analysis included 306 patients with advanced gastric cancer and evaluable TMB data who received pembrolizumab alone, pembrolizumab+chemotherapy, or chemotherapy alone in the phase 3 KEYNOTE-062 trial (n = 763).

Disclosures: This study was sponsored by Merck Sharp & Dohme (MSD) LLC, a subsidiary of Merck & Co., Inc., NJ Some authors reported receiving grants or personal fees from various sources, including MSD and Merck. Two authors declared being employees of MSD or Merck.

Source: Lee KW et al. Association of tumor mutational burden with efficacy of pembrolizumab±chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 2022;28(16):3489-3498 (Aug 15). Doi: 10.1158/1078-0432.CCR-22-0121

Key clinical point: Tumor mutational burden (TMB) status is associated with the clinical outcomes of the first-line pembrolizumab-based therapy in patients with advanced gastric cancer.

Major finding: TMB was significantly associated with the objective response rate, progression-free survival, and overall survival in the pembrolizumab monotherapy and pembrolizumab-chemotherapy treatment groups (1-sided P < .05) but not in the chemotherapy group (2-sided P > .05).

Study details: This prespecified exploratory analysis included 306 patients with advanced gastric cancer and evaluable TMB data who received pembrolizumab alone, pembrolizumab+chemotherapy, or chemotherapy alone in the phase 3 KEYNOTE-062 trial (n = 763).

Disclosures: This study was sponsored by Merck Sharp & Dohme (MSD) LLC, a subsidiary of Merck & Co., Inc., NJ Some authors reported receiving grants or personal fees from various sources, including MSD and Merck. Two authors declared being employees of MSD or Merck.

Source: Lee KW et al. Association of tumor mutational burden with efficacy of pembrolizumab±chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 2022;28(16):3489-3498 (Aug 15). Doi: 10.1158/1078-0432.CCR-22-0121

Key clinical point: Intensive index endoscopy in individuals with high risk for gastric cancer does not reduce the detection rate of new gastric cancers after 1 year.

Major finding: The rate of early gastric cancer detection by index endoscopy was similar to that of new gastric cancer detection by surveillance endoscopy within 15 months after index endoscopy (3.0% vs 2.6%).

Study details: This case-control secondary analysis of the data of 4523 individuals with high risk for gastric cancer from a randomized clinical trial who received index endoscopy comprising two examinations of the stomach with white light and narrow-band imaging.

Disclosures: This study was sponsored by Kyoto University, Japan, and Olympus Medical Systems. Some authors reported receiving grants or personal fees from various sources, including Olympus Medical Systems.

Source: Yamamoto Y et al. Assessment of outcomes from 1-year surveillance after detection of early gastric cancer among patients at high risk in Japan. JAMA Netw Open. 2022;5(8):e2227667 (Aug 19). Doi: 10.1001/jamanetworkopen.2022.27667

Key clinical point: Intensive index endoscopy in individuals with high risk for gastric cancer does not reduce the detection rate of new gastric cancers after 1 year.

Major finding: The rate of early gastric cancer detection by index endoscopy was similar to that of new gastric cancer detection by surveillance endoscopy within 15 months after index endoscopy (3.0% vs 2.6%).

Study details: This case-control secondary analysis of the data of 4523 individuals with high risk for gastric cancer from a randomized clinical trial who received index endoscopy comprising two examinations of the stomach with white light and narrow-band imaging.

Disclosures: This study was sponsored by Kyoto University, Japan, and Olympus Medical Systems. Some authors reported receiving grants or personal fees from various sources, including Olympus Medical Systems.

Source: Yamamoto Y et al. Assessment of outcomes from 1-year surveillance after detection of early gastric cancer among patients at high risk in Japan. JAMA Netw Open. 2022;5(8):e2227667 (Aug 19). Doi: 10.1001/jamanetworkopen.2022.27667

Key clinical point: Intensive index endoscopy in individuals with high risk for gastric cancer does not reduce the detection rate of new gastric cancers after 1 year.

Major finding: The rate of early gastric cancer detection by index endoscopy was similar to that of new gastric cancer detection by surveillance endoscopy within 15 months after index endoscopy (3.0% vs 2.6%).

Study details: This case-control secondary analysis of the data of 4523 individuals with high risk for gastric cancer from a randomized clinical trial who received index endoscopy comprising two examinations of the stomach with white light and narrow-band imaging.

Disclosures: This study was sponsored by Kyoto University, Japan, and Olympus Medical Systems. Some authors reported receiving grants or personal fees from various sources, including Olympus Medical Systems.

Source: Yamamoto Y et al. Assessment of outcomes from 1-year surveillance after detection of early gastric cancer among patients at high risk in Japan. JAMA Netw Open. 2022;5(8):e2227667 (Aug 19). Doi: 10.1001/jamanetworkopen.2022.27667

Key clinical point: Intraperitoneal paclitaxel (IP-PTX) combined with capecitabine/oxaliplatin (XELOX) in patients with gastric cancer peritoneal metastases (GCPM) is safe and improves survival outcomes compared with systemic chemotherapy (SC) alone.

Major finding: After a median follow-up of 12.1 months, patients receiving IP-PTX+XELOX vs SC had a significantly longer median overall survival (14.6 vs 10.6 months; hazard ratio [HR] 0.44; P = .002) and progression-free survival (9.5 vs 4.4 months; HR 0.39; P < .001). The Common Terminology Criteria for Adverse Event grade 5 complication rate with IP-PTX+XELOX was 5%.

Study details: This prospective phase 2 study analyzed IP-PTX+XELOX treatment outcomes in 44 patients with GCPM and compared them with SC (fluoropyrimidine/platinum doublet) treatment outcomes in a matched retrospective cohort of 39 patients with GCPM.

Disclosures: This study was sponsored by the National Medical Research Council, Singapore. S Raghav declared serving as an advisory board member of and receiving speaker honoraria and research funding from various sources.

Source: Chia DKA et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022 (Sep 7). Doi: 10.1245/s10434-022-11998-z

Key clinical point: Intraperitoneal paclitaxel (IP-PTX) combined with capecitabine/oxaliplatin (XELOX) in patients with gastric cancer peritoneal metastases (GCPM) is safe and improves survival outcomes compared with systemic chemotherapy (SC) alone.

Major finding: After a median follow-up of 12.1 months, patients receiving IP-PTX+XELOX vs SC had a significantly longer median overall survival (14.6 vs 10.6 months; hazard ratio [HR] 0.44; P = .002) and progression-free survival (9.5 vs 4.4 months; HR 0.39; P < .001). The Common Terminology Criteria for Adverse Event grade 5 complication rate with IP-PTX+XELOX was 5%.

Study details: This prospective phase 2 study analyzed IP-PTX+XELOX treatment outcomes in 44 patients with GCPM and compared them with SC (fluoropyrimidine/platinum doublet) treatment outcomes in a matched retrospective cohort of 39 patients with GCPM.

Disclosures: This study was sponsored by the National Medical Research Council, Singapore. S Raghav declared serving as an advisory board member of and receiving speaker honoraria and research funding from various sources.

Source: Chia DKA et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022 (Sep 7). Doi: 10.1245/s10434-022-11998-z

Key clinical point: Intraperitoneal paclitaxel (IP-PTX) combined with capecitabine/oxaliplatin (XELOX) in patients with gastric cancer peritoneal metastases (GCPM) is safe and improves survival outcomes compared with systemic chemotherapy (SC) alone.

Major finding: After a median follow-up of 12.1 months, patients receiving IP-PTX+XELOX vs SC had a significantly longer median overall survival (14.6 vs 10.6 months; hazard ratio [HR] 0.44; P = .002) and progression-free survival (9.5 vs 4.4 months; HR 0.39; P < .001). The Common Terminology Criteria for Adverse Event grade 5 complication rate with IP-PTX+XELOX was 5%.

Study details: This prospective phase 2 study analyzed IP-PTX+XELOX treatment outcomes in 44 patients with GCPM and compared them with SC (fluoropyrimidine/platinum doublet) treatment outcomes in a matched retrospective cohort of 39 patients with GCPM.

Disclosures: This study was sponsored by the National Medical Research Council, Singapore. S Raghav declared serving as an advisory board member of and receiving speaker honoraria and research funding from various sources.

Source: Chia DKA et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022 (Sep 7). Doi: 10.1245/s10434-022-11998-z

Key clinical point: Elevated pretreatment plasma levels of programmed death-ligand 1 (PD-L1) predicted poor disease-specific survival (DSS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).

Major finding: The pretreatment PD-L1 levels were significantly lower in patients with metachronous vs synchronous metastases (P  =  .0412) and in those without vs with signs of disease progression (P  =  .0443), with a significant association observed between elevated PD-L1 levels and shorter DSS (P  =  .0257) and PFS (P  =  .0141).

Study details: Findings are from a retrospective analysis of 37 patients with stage IV mCRC who were included prior to any metastatic setting treatments.

Disclosures: This study was supported by the National Research, Development, and Innovation Office, Hungary. The authors declared no conflicts of interest.

Source: Dank M et al. Does elevated pre-treatment plasma PD-L1 level indicate an increased tumor burden and worse prognosis in metastatic colorectal cancer? J Clin Med. 2022;11(16):4815 (Aug 17). Doi: 10.3390/jcm11164815

Key clinical point: Elevated pretreatment plasma levels of programmed death-ligand 1 (PD-L1) predicted poor disease-specific survival (DSS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).

Major finding: The pretreatment PD-L1 levels were significantly lower in patients with metachronous vs synchronous metastases (P  =  .0412) and in those without vs with signs of disease progression (P  =  .0443), with a significant association observed between elevated PD-L1 levels and shorter DSS (P  =  .0257) and PFS (P  =  .0141).

Study details: Findings are from a retrospective analysis of 37 patients with stage IV mCRC who were included prior to any metastatic setting treatments.

Disclosures: This study was supported by the National Research, Development, and Innovation Office, Hungary. The authors declared no conflicts of interest.

Source: Dank M et al. Does elevated pre-treatment plasma PD-L1 level indicate an increased tumor burden and worse prognosis in metastatic colorectal cancer? J Clin Med. 2022;11(16):4815 (Aug 17). Doi: 10.3390/jcm11164815

Key clinical point: Elevated pretreatment plasma levels of programmed death-ligand 1 (PD-L1) predicted poor disease-specific survival (DSS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).

Major finding: The pretreatment PD-L1 levels were significantly lower in patients with metachronous vs synchronous metastases (P  =  .0412) and in those without vs with signs of disease progression (P  =  .0443), with a significant association observed between elevated PD-L1 levels and shorter DSS (P  =  .0257) and PFS (P  =  .0141).

Study details: Findings are from a retrospective analysis of 37 patients with stage IV mCRC who were included prior to any metastatic setting treatments.

Disclosures: This study was supported by the National Research, Development, and Innovation Office, Hungary. The authors declared no conflicts of interest.

Source: Dank M et al. Does elevated pre-treatment plasma PD-L1 level indicate an increased tumor burden and worse prognosis in metastatic colorectal cancer? J Clin Med. 2022;11(16):4815 (Aug 17). Doi: 10.3390/jcm11164815

Key clinical point: The coadministration of histamine H₂ receptor antagonists (H₂RA) is unlikely to affect the efficacy of capecitabine monotherapy and capecitabine and oxaliplatin (CapeOX) regimen in patients with early-stage colorectal cancer (CRC).

Major finding: At 5 years, the relapse-free survival (RFS) in the H₂RA and non-H₂RA groups were 76.7% (95% CI 57.2%-88.1%) and 79.8% (95% CI 76.0%-83.0%), respectively, with RFS not being significantly different between the H₂RA and non-H₂RA groups of patients receiving capecitabine monotherapy or CapeOX (P  =  .772).

Study details: Findings are from a retrospective analysis of 552 patients with stage II-III CRC who received either capecitabine alone or CapeOX as adjuvant therapy. H₂RA were coadministered to 30 patients.

Disclosures: This study was partly supported by the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research and the Policy-based Medical Services Foundation in Japan. R Uozumi and H Kawazoe declared ties with various sources.

Source: Yamazaki T et al. Association between the co-administration of histamine H₂ receptor antagonists and the effectiveness of capecitabine in patients with colorectal cancer: Propensity score analysis. J Cancer. 2022;13(10):3073-3083 (Aug 8). Doi: 10.7150/jca.73385

Key clinical point: The coadministration of histamine H₂ receptor antagonists (H₂RA) is unlikely to affect the efficacy of capecitabine monotherapy and capecitabine and oxaliplatin (CapeOX) regimen in patients with early-stage colorectal cancer (CRC).

Major finding: At 5 years, the relapse-free survival (RFS) in the H₂RA and non-H₂RA groups were 76.7% (95% CI 57.2%-88.1%) and 79.8% (95% CI 76.0%-83.0%), respectively, with RFS not being significantly different between the H₂RA and non-H₂RA groups of patients receiving capecitabine monotherapy or CapeOX (P  =  .772).

Study details: Findings are from a retrospective analysis of 552 patients with stage II-III CRC who received either capecitabine alone or CapeOX as adjuvant therapy. H₂RA were coadministered to 30 patients.

Disclosures: This study was partly supported by the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research and the Policy-based Medical Services Foundation in Japan. R Uozumi and H Kawazoe declared ties with various sources.

Source: Yamazaki T et al. Association between the co-administration of histamine H₂ receptor antagonists and the effectiveness of capecitabine in patients with colorectal cancer: Propensity score analysis. J Cancer. 2022;13(10):3073-3083 (Aug 8). Doi: 10.7150/jca.73385

Key clinical point: The coadministration of histamine H₂ receptor antagonists (H₂RA) is unlikely to affect the efficacy of capecitabine monotherapy and capecitabine and oxaliplatin (CapeOX) regimen in patients with early-stage colorectal cancer (CRC).

Major finding: At 5 years, the relapse-free survival (RFS) in the H₂RA and non-H₂RA groups were 76.7% (95% CI 57.2%-88.1%) and 79.8% (95% CI 76.0%-83.0%), respectively, with RFS not being significantly different between the H₂RA and non-H₂RA groups of patients receiving capecitabine monotherapy or CapeOX (P  =  .772).

Study details: Findings are from a retrospective analysis of 552 patients with stage II-III CRC who received either capecitabine alone or CapeOX as adjuvant therapy. H₂RA were coadministered to 30 patients.

Disclosures: This study was partly supported by the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research and the Policy-based Medical Services Foundation in Japan. R Uozumi and H Kawazoe declared ties with various sources.

Source: Yamazaki T et al. Association between the co-administration of histamine H₂ receptor antagonists and the effectiveness of capecitabine in patients with colorectal cancer: Propensity score analysis. J Cancer. 2022;13(10):3073-3083 (Aug 8). Doi: 10.7150/jca.73385

Key clinical point: This real-world study confirms the efficacy and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer (mCRC), with a tolerability and safety profile consistent with previous reports.

Major finding: After a median follow-up of 11.6 months, the overall response rate and disease control rate were 3.2% and 51.6%, respectively, with the median progression-free survival and overall survival being 4.3 months (95% CI 3.4-5.1) and 9.3 months (95% CI 6.6-12.1), respectively. Neutropenia (45.7%), asthenia (17.1%), and nausea/vomiting (8.6%) were the most common grade 3-4 adverse events.

Study details: Findings are from a retrospective study including 35 patients with mCRC who were refractory or intolerant to standard therapies and received trifluridine/tipiracil plus bevacizumab.

Disclosures: This study was funded by the Biomedical Research Institute of A Coruña, Spain. The authors declared no competing interests.

Source: Martínez-Lago N et al. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Sci Rep. 2022;12(1):14612 (Aug 26). Doi: 10.1038/s41598-022-18871-9

Key clinical point: This real-world study confirms the efficacy and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer (mCRC), with a tolerability and safety profile consistent with previous reports.

Major finding: After a median follow-up of 11.6 months, the overall response rate and disease control rate were 3.2% and 51.6%, respectively, with the median progression-free survival and overall survival being 4.3 months (95% CI 3.4-5.1) and 9.3 months (95% CI 6.6-12.1), respectively. Neutropenia (45.7%), asthenia (17.1%), and nausea/vomiting (8.6%) were the most common grade 3-4 adverse events.

Study details: Findings are from a retrospective study including 35 patients with mCRC who were refractory or intolerant to standard therapies and received trifluridine/tipiracil plus bevacizumab.

Disclosures: This study was funded by the Biomedical Research Institute of A Coruña, Spain. The authors declared no competing interests.

Source: Martínez-Lago N et al. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Sci Rep. 2022;12(1):14612 (Aug 26). Doi: 10.1038/s41598-022-18871-9

Key clinical point: This real-world study confirms the efficacy and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer (mCRC), with a tolerability and safety profile consistent with previous reports.

Major finding: After a median follow-up of 11.6 months, the overall response rate and disease control rate were 3.2% and 51.6%, respectively, with the median progression-free survival and overall survival being 4.3 months (95% CI 3.4-5.1) and 9.3 months (95% CI 6.6-12.1), respectively. Neutropenia (45.7%), asthenia (17.1%), and nausea/vomiting (8.6%) were the most common grade 3-4 adverse events.

Study details: Findings are from a retrospective study including 35 patients with mCRC who were refractory or intolerant to standard therapies and received trifluridine/tipiracil plus bevacizumab.

Disclosures: This study was funded by the Biomedical Research Institute of A Coruña, Spain. The authors declared no competing interests.

Source: Martínez-Lago N et al. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting. Sci Rep. 2022;12(1):14612 (Aug 26). Doi: 10.1038/s41598-022-18871-9